

SenzaGen appoints new Chief Scientific Officer

Lund, March 7, 2018 - SenzaGen (Nasdaq First North: SENZA) today announced that the company has recruited Dr Gunilla Grundström as its new Chief Scientific Officer. She has more than 10 years of commercial experience in the pharmaceutical and medical technology industry and comes most recently from a position as Senior Research Manager at Baxter.

Gunilla Grundström holds a Masters degree from Lund University and has a Ph.D. in medical biochemistry. She has previously held senior positions within AstraZeneca's and Gambro's research organizations, and since 2013 she has been Senior Research Manager at Baxter in Lund. In her role as Chief Scientific Officer (CSO) she will be responsible for SenzaGen's long-term development strategy and product portfolio.

"Gunilla has a solid scientific background, many years' experience in managing complex research and development projects and an excellent understanding of the customer needs that we strive to satisfy. I look forward to her contribution towards the development of new products based on our unique technology platform GARD," says SenzaGen's CEO, Anki Malmberg Hager.

Gunilla Grundström takes up her position at SenzaGen on 1st May 2018. She succeeds Henrik Appelgren, who for personal reasons is moving to a part-time role in the company focusing on regulatory issues.

For more information, please contact:

Anki Malmberg Hager, CEO, SenzaGen AB
Email: anki.malmberg.hager@senzagen.com
Telephone: +46 768 284822

About GARD™

GARD™ is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90 percent reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75 percent. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently, GARD tests provide a much more comprehensive

SENZAGEN AB

MEDICON VILLAGE,
SCHEELEVÄGEN 2
223 81 LUND, SWEDEN

P: +46 46 2756200
W: WWW.SENZAGEN.COM
E: INFO@SENZAGEN.COM

basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen

SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com

The information was submitted for publication, through the contact person set out above on March 7, 2018 at 08:45 CET

SenzaGen AB are listed on Nasdaq First North in Stockholm and FNCA is the company's Certified Adviser. For more information, please visit www.senzagen.com